ASDERA develops interventions for unmet needs by utilizing a patented computational biostatistics platform to identify complex genetic risk factors in small (from n≈500) epidemiological and 'failed' phase 2/3 studies.

  The ASDERA time-/pipeline:

1. Validation: Confirmation of known drug targets in epilepsy
   (2013, Pharmacogenomics)
2. Proof-of-principle: L-fucose in Crohn's disease 
   (in progress, from 2006 dbGaP data)
3. Autism: A derivative of mefenamic acid against mutism in autism (2014, Nature: Transl. Psychiatry, $500M valuation)
4. Lysosome function treatments: Intestinally absorbed derivatives of HP-a-cyclodextrin  (pat. pending) against progression of
   - carcinomas (breast cancer, ^{https://doi.org/10.1371/journal.pone.0199012})
   - neurodegeneration (Alzheimer's, Parkinson's, Huntingtion's, ...) 
5. - lysosomal storage diseases (NPC, TS, Fabry, Sandhoff, Farber, ...)
6. Nutritional products: Novel formulation of a-cyclodextrin (pat. pending) for use in dietary supplements and food as
   - 'fasting mimetic' to improve the natural process of aging
7. - 'adaptive vaccination' to reduce severity of initial infection with
      SARS-CoV-2 while developing COVID-19 immunity.